Systemic therapy in the palliative management of advanced salivary gland cancers (review)
This review of chemotherapy in salivary gland cancers concluded that responses are uncommon and short, that observation is reasonable for slowly progressing disease, and that trials of targeted agents based on tumour biology were needed.
Overview
Systematic review of systemic therapy studies in recurrent or metastatic salivary gland carcinoma, summarising response rates to single agents and combinations by histology, the natural history of indolent adenoid cystic carcinoma, and early experience with targeted agents.
The observation-first approach for indolent metastases and the move to biomarker-directed therapy (HER2, androgen receptor, NTRK) on the salivary cancer pages follow this review's conclusions.
- Predates the HER2, androgen receptor and immunotherapy studies that now guide treatment.
Similar pages
not linked directly; found by shared links- Key paperPhase 2 study of lenvatinib in progressive, recurrent or metastatic adenoid cystic carcinoma
Shares Adenoid cystic carcinoma, Journal of Clinical Oncology.
- Key paperPhase 2 trial of trastuzumab and docetaxel in HER2-positive salivary duct carcinoma
Shares Salivary duct carcinoma, Journal of Clinical Oncology.
- Key paperEORTC 22931: postoperative irradiation with or without concomitant cisplatin for locally advanced head and neck cancer
- TermExtranodal extension (ENE)
- CancerSalivary gland cancers
Shares Mucoepidermoid carcinoma, Adenoid cystic carcinoma, Salivary duct carcinoma.